scholarly journals Nomograms for predicting cancer-specific survival in patients with primary central nervous system lymphoma: a population- based analysis

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
Chuanwei Yang ◽  
Xiaohui Ren ◽  
Yong Cui ◽  
Haihui Jiang ◽  
Kefu Yu ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Lymphoma ◽  
Population Based ◽  
Cancer Specific Survival

scholarly journals Population-Based Incidence and Outcome of Primary Central Nervous System Lymphoma – a Study By the Austrian Brain Tumor Registry, 2005–2010

2014 ◽  
Vol 25 ◽  
pp. iv144
Author(s):  
A. Woehrer ◽  
M. Hackl ◽  
T. Waldhör ◽  
J. Hainfellner ◽  
A.S. Berghoff ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Brain Tumor ◽  
Central Nervous System Lymphoma ◽  
Population Based ◽  
Tumor Registry

scholarly journals Conditional relative survival in primary central nervous system lymphoma: a population-based study in the Netherlands

2020 ◽  
Vol 2 (1) ◽  
Author(s):  
Avinash G Dinmohamed ◽  
Matthijs van der Meulen ◽  
Otto Visser ◽  
Jeanette K Doorduijn ◽  
Jacoline E C Bromberg
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
The Netherlands ◽  
Central Nervous System Lymphoma ◽  
Relative Survival ◽  
Population Based ◽  
Population Based Study

Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015

Leukemia ◽  
2017 ◽  
Vol 31 (8) ◽  
pp. 1822-1825 ◽  
Author(s):  
M van der Meulen ◽  
A G Dinmohamed ◽  
O Visser ◽  
J K Doorduijn ◽  
J E C Bromberg
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
The Netherlands ◽  
Central Nervous System Lymphoma ◽  
Primary Treatment ◽  
Population Based ◽  
Population Based Study

scholarly journals Population-based Incidence and Survival for Primary Central Nervous System Lymphoma in Korea, 1999-2009

2015 ◽  
Vol 47 (4) ◽  
pp. 569-574 ◽  
Author(s):  
Sang-Hoon Shin ◽  
Kyu-Won Jung ◽  
Johyun Ha ◽  
Seung Hoon Lee ◽  
Young-Joo Won ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Lymphoma ◽  
Population Based

scholarly journals Changing Incidence and Survival of Primary Central Nervous System Lymphoma in Australia: A 33-Year National Population-Based Study

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 403
Author(s):  
Alexandra L. Farrall ◽  
Justine R. Smith
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Confidence Interval ◽  
Median Survival ◽  
Survival Probability ◽  
Central Nervous System Lymphoma ◽  
B Cell Lymphoma ◽  
Population Based ◽  
Incidence Rates ◽  
Cns Lymphoma

Primary central nervous system lymphoma (PCNSL) is a rare brain cancer that remains challenging to study. Epidemiology of PCNSL in the Australian population, which is racially and ethnically diverse, has not been examined previously. Using ICD-O-3.1 Morphology and Topography Codes to identify cases, we analyzed complete datasets from the comprehensive Australian Cancer Database (1982–2014, adults aged ≥ 20 years) to establish incidence rates and trends of PCNSL, and to define survival outcomes of individuals diagnosed with PCNSL, including the predominant diffuse large B-cell lymphoma (DLBCL) type. Age-standardized incidence of PCNSL increased by an average annual 6.8% percent over the study period, with current incidence of 0.43 (95% confidence interval, 0.41–0.46) per 100,000 person-years, in comparison to 21.89 (21.41–22.38) per 100,000 person-years for non-CNS lymphoma. Increase in incidence was characterized by an acute rise between 1996 and 1999, was more pronounced with increasing age, and was driven by increasing incidence of DLBCL. Overall survival for persons diagnosed with PCNSL improved significantly across the study period, with 5-year survival probability increasing from 0.21 (95% confidence interval, 0.16–0.26) to 0.33 (0.30–0.36), and median survival increasing from 318 to 600 days, between 1982–1999 and 2000–2014. Increase in survival was significantly higher for persons with DLBCL versus non-DLBCL PCNSL, but substantially lower than that for persons with non-CNS lymphoma, who had a 5-year survival probability of 0.62 (0.62–0.62) and a median survival of 3388 days in 2000–2014. This study links increasing incidence of PCNSL in Australia to increasing incidence of DLCBL, including in younger adults, and highlights the improving, but low, survival outcome of this cancer.

scholarly journals Primary Central Nervous System Lymphoma High Incidence And Poor Survival In Finnish Population-Based Analysis

2021 ◽  
Author(s):  
Inka Puhakka ◽  
Hanne Kuitunen ◽  
Pekka Jäkälä ◽  
Eila Sonkajärvi ◽  
Taina Turpeenniemi-Hujanen ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Survival Rate ◽  
Survival Rates ◽  
Central Nervous System Lymphoma ◽  
Relative Survival ◽  
B Cell Lymphoma ◽  
Population Based ◽  
Incidence Rates ◽  
Relative Survival Rate

Abstract Background: We report here the first population-based incidence rates and prognosis of primary central nervous system lymphoma (PCNSL) in Finland. Methods: Finnish Cancer Registry data by histological diagnosis and tumor location (2007-2017) for cases with diffuse large B-cell lymphoma.Results: During 2007–2017, 392 new cases of PCNSL were reported (195 males, 197 females). The average age-adjusted incidence was 0.68/100.000 person-years. Incidence for males was 0.74/100.000 and for females 0.63/100.000, respectively. The incidence was highest, 2.93/100.000, among people aged 75–79 years. Concerning all cases in 2007-2017 the 2-year age-adjusted relative survival rate was 35% and the corresponding 5-year survival rate was 28%. Among patients under the age of 70, the age-adjusted 5-year relative survival rate increased from 36% in 2007-2012 to 43% for 2013-2017. Among patients aged 70+ the corresponding survival rates were poor, 7% and 9%.Conclusions: PCNSL incidence in Finland is among the highest reported in the world. The annual increase in incidence was 2.4%. The prognosis is still dismal, especially in elderly patients.

scholarly journals OS10.3 Primary therapy and survival in over 70-year-old patients with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii21-iii21
Author(s):  
M van der Meulen ◽  
J E C Bromberg ◽  
O Visser ◽  
J K Doorduijn ◽  
A G Dinmohamed
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
The Netherlands ◽  
Elderly Patients ◽  
Age Groups ◽  
Central Nervous System Lymphoma ◽  
Population Based ◽  
Primary Therapy ◽  
Age Group ◽  
Population Based Study

Abstract BACKGROUND Elderly patients with primary central nervous system lymphoma (PCNSL) have a poor prognosis. In this contemporary, nationwide, population-based study, we assessed the contribution of primary therapy on overall survival (OS) among elderly PCNSL patients in the Netherlands. METHODS All patients aged ≥ 70 years with cytologically and/or histologically proven PCNSL diagnosed between 2014–2016 were selected from the nationwide Netherlands Cancer Registry. Univariable analysis of OS was performed with the log-rank test. Multivariable Cox regression was applied to assess factors associated with OS, with adjustment for age (71–74, 75–79 and ≥80 years), sex, prior malignancy, primary therapy (no therapy, radiotherapy [RT] only, chemotherapy [CT]), and rituximab treatment. RESULTS Overall, 109 patients were registered; 39%, 39%, and 22% were aged 71–74, 75–79 and ≥80 years, respectively. Most patients received CT (45%), followed by no therapy (33%) and RT only (22%). With increasing age, the application of CT decreased (60%, 43%, and 24%), and RT only increased (10%, 26%, 26%) in the three age groups. CT consisted of methotrexate (MTX)-based or MTX only regimens in 98%. In patients treated with CT, Rituximab was added in 31%. During follow-up, 89 patients (82%) died. Median OS was 5.3 months (95% confidence interval [CI], 3.3–7.8), no difference was observed in median OS across the three age groups (6.8, 4.4, and 4.6 months, respectively; P=0.348). However, in the groups no therapy, RT only, and CT, median OS (95% CI) was 1.3 (1.0–2.0), 6.5 (4.4–12.5), and 20.3 (8.6–41.4) months (P<0.001), respectively. Moreover, 2 year OS (95%CI) was 49% (34–62) in patients treated with chemotherapy compared with 17% (5–34) in patients treated with RT. Median OS (95% CI) was 20.3 (8.6–41.4) in recipients of MTX-based regimens and 5.0 (2.4-not reached) months in recipients MTX only (P=0.185). In multivariable analysis, treatment with CT or RT was the only factor associated with OS: age group and the addition of Rituximab were not associated with OS. CONCLUSION In this contemporary population-based study, OS remained poor among patients with PCNSL aged over 70 years, irrespective of age group. Clinical condition likely influenced therapy choices but in those judged fit enough to receive CT, almost 50% survived 2 years. Therefore, future prospective intervention studies are warranted to assess which group of elderly patients benefit from CT or less intensive approaches.

scholarly journals Primary Central Nervous System Lymphoma Increasing Incidence and Poor Survival: A Finnish Population-based Analysis

2021 ◽  
Author(s):  
Inka Puhakka ◽  
Outi Kuittinen ◽  
Pekka Jäkälä ◽  
Hanne Kuitunen ◽  
Taina Turpeenniemi-Hujanen ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Survival Rates ◽  
Central Nervous System Lymphoma ◽  
Tumor Location ◽  
Population Based ◽  
Incidence Rates ◽  
Cancer Registry Data ◽  
A Minor ◽  
Adjusted Incidence

Abstract PurposeWe report here the first population-based incidence rates and prognosis of primary central nervous system lymphoma (PCNSL) in Finland. MethodsFinnish Cancer Registry data by histological diagnosis and tumor location (2007-2017) for cases with diffuse large B-cell lymphoma.ResultsDuring 2007–2017, 416 new cases of PCNSL were reported (202 males, 214 females). The average age-adjusted incidence in males vs. females for 2007-2009, 2010-2012, 2013-2015 and 2016-2017 was 0.57/100,000 vs. 0.48/100,000 person-years, 0.66/100,000 vs. 0.55/100,000, 0.53/100,000 vs. 0.63/100,000, and 0.76/100,000 vs. 0.66/100,000 respectively. The incidence was highest, 3.27/100,000, among people aged 75–79 years. From 2007–2012 to 2013–2017, the 2-year age-adjusted survival rate increased from 36% to 41%, and the 4-year survival rates from 31% to 37%. Among patients aged 70+ years, the corresponding 2-year survival rates were 25% and 29%, and the 4-year survival rates 25% and 22%.ConclusionAge-adjusted incidence of PCNSL increased from 0.57/100,000 (2007–2012) to 0.63/100,000 (2013–2017). The annual increase was 3.8% being among the highest reported in the world. The prognosis was poor, although a minor improvement in 4-year survival was found.

scholarly journals Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands

Haematologica ◽  
2020 ◽  
pp. haematol.2020.247536 ◽  
Author(s):  
Matthijs van der Meulen ◽  
Jacoline E.C. Bromberg ◽  
Marcel Nijland ◽  
Otto Visser ◽  
Jeanette K. Doorduijn ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
The Netherlands ◽  
Central Nervous System Lymphoma ◽  
Population Based ◽  
Primary Therapy ◽  
Population Based Study
Sign in / Sign up

Export Citation Format

Share Document